作者
Juraj Velcicky,Matthias R. Bauer,Achim Schlapbach,Guillaume Lapointe,Arndt Meyer,Markus Vögtle,Ernst Blum,E O Ngo,C. ROLANDO,Pierre Nimsgern,Sylvie Teixeira-Fouchard,Hansjoerg Lehmann,Pascal Furet,Frédéric Berst,Jens Schümann,Rowan Stringer,Patrice Larger,Cindy Schmid,Catriona T. Prendergast,Simone Riek,Patrick Schmutz,Sylvie Lehmann,Jörg Berghausen,Clemens Scheufler,Jean‐Michel Rondeau,Christoph Burkhart,Thomas Knoepfel,Nina Gommermann
摘要
IL-17, a pro-inflammatory cytokine produced mainly by Th17 cells, is involved in the immune response to fungal and bacterial infections, whereas its aberrant production is associated with autoimmune and inflammatory diseases. IL-17 blocking antibodies like secukinumab (Cosentyx) have been developed and are used to treat conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. Recently, the low molecular weight IL-17 inhibitor LY3509754 entered the clinic but was discontinued in Phase 1 due to adverse effects. In this study, we explored the replacements of furazan moiety posing a potential toxicology risk in LY3509754. By exploring replacements such as heterocycles as amide-isosteres as well as α-F-acrylamides, two compounds (